CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
rhuFab V2 (ranibizumab)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00090623
NCT00090623Phase 3Completed
CompareCT.gov

A Phase IIIb, Multicenter, Randomized, Double Masked, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab in Subjects With Subfoveal Choroidal Neovascularization (CNV) With or Without Classic CNV Secondary to Age Related Macular Degeneration

Genentech, Inc.·interventional·Posted Sep 1, 2004·Updated Jun 21, 2013

In Brief

A Phase 3 clinical trial evaluating rhuFab V2 (ranibizumab) for Macular Degeneration. Completed, across 1 site.

Detailed Summary

This is a phase III, multicenter, randomized, double masked, sham injection-controlled study of the efficacy and safety of intravitreally administered ranibizumab in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMacular Degeneration
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 1, 2004
Enrollment StartAug 1, 2004
Study CompletionMar 1, 2007
TodayJul 2, 2026
Posted 21.8 years ago

Interventions

rhuFab V2 (ranibizumab)drug